Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Financing Activities (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Cash from Financing Activities for 6 consecutive years, with -$252000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 102.33% to -$252000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.1 million through Dec 2025, up 37.41% year-over-year, with the annual reading at $28.1 million for FY2025, 37.41% up from the prior year.
  • Cash from Financing Activities hit -$252000.0 in Q4 2025 for Insight Molecular Diagnostics, down from -$120000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $69.9 million in Q1 2021 to a low of -$528000.0 in Q3 2022.
  • Historically, Cash from Financing Activities has averaged $9.2 million across 5 years, with a median of -$30000.0 in 2023.
  • Biggest YoY gain for Cash from Financing Activities was 36223.33% in 2024; the steepest drop was 750.0% in 2024.
  • Year by year, Cash from Financing Activities stood at -$269000.0 in 2021, then surged by 62.83% to -$100000.0 in 2022, then surged by 70.0% to -$30000.0 in 2023, then soared by 36223.33% to $10.8 million in 2024, then crashed by 102.33% to -$252000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for IMDX at -$252000.0 in Q4 2025, -$120000.0 in Q3 2025, and -$114000.0 in Q2 2025.